Recursion Pharmaceuticals

Recursion Pharmaceuticals Revenue

The The revenue of Recursion Pharmaceuticals (RXRX) as of Nov 20, 2026 is 74.68 M USD. In the previous year, The revenue was 58.84 M USD — a change of 26.92% (higher).

Revenue

74.68 MUSD

YoY

26.92%

Last updated:

In 2025, Recursion Pharmaceuticals's sales reached 74.68 M USD, a 26.92% difference from the 58.84 M USD sales recorded in the previous year.

Revenue has compounded at 87.6% per year over the past 6 years to 74.68 M USD.

The Recursion Pharmaceuticals Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2022
39.68 M USD
Jan 1, 2023
43.88 M USD
Jan 1, 2024
58.84 M USD
Jan 1, 2025
74.68 M USD
Jan 1, 2026 (e)
40.30 M USD
Jan 1, 2027 (e)
44.31 M USD
Jan 1, 2028 (e)
38.44 M USD
Jan 1, 2029 (e)
247.50 M USD
The Recursion Pharmaceuticals Revenue history
YEARRevenueYoY
est247.50 MUSD+543.83%
est38.44 MUSD-13.24%
est44.31 MUSD+9.94%
est40.30 MUSD-46.03%
74.68 MUSD+26.92%
58.84 MUSD+34.10%
43.88 MUSD+10.57%
39.68 MUSD+296.81%
10.00 MUSD+193.00%
3.41 MUSD+99.47%
1.71 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Revenue

Recursion Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
39.68 M USD
-245.73 M USD
-239.42 M USD
Jan 1, 2023
43.88 M USD
-350.06 M USD
-328.07 M USD
Jan 1, 2024
58.84 M USD
-479.00 M USD
-463.66 M USD
Jan 1, 2025
74.68 M USD
-648.13 M USD
-644.76 M USD
Jan 1, 2026 (e)
40.30 M USD
-396.94 M USD
-457.38 M USD
Jan 1, 2027 (e)
44.31 M USD
-353.66 M USD
-422.28 M USD
Jan 1, 2028 (e)
38.44 M USD
-336.35 M USD
-393.00 M USD
Jan 1, 2029 (e)
247.50 M USD
-419.44 M USD
-488.65 M USD

Recursion Pharmaceuticals Margins

Recursion Pharmaceuticals stock margins

The Recursion Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Recursion Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Recursion Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
-21.66 %
-619.26 %
-603.36 %
Jan 1, 2023
2.94 %
-797.84 %
-747.71 %
Jan 1, 2024
23.12 %
-814.09 %
-788.02 %
Jan 1, 2025
-61.96 %
-867.87 %
-863.35 %
Jan 1, 2026 (e)
-61.96 %
-984.86 %
-1,134.80 %
Jan 1, 2027 (e)
-61.96 %
-798.15 %
-953.02 %
Jan 1, 2028 (e)
-61.96 %
-874.97 %
-1,022.33 %
Jan 1, 2029 (e)
-61.96 %
-169.47 %
-197.43 %

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Recursion Pharmaceuticals's Sales Figures

The sales figures of Recursion Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Recursion Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Recursion Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Recursion Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Recursion Pharmaceuticals stock

The revenue of Recursion Pharmaceuticals is 74.68 M USD in 2025.

The revenue of Recursion Pharmaceuticals changed from 58.84 M USD to 74.68 M USD, representing a 26.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Recursion Pharmaceuticals historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals